Blockade of PD-1 by anti-PD-1 antibody has been tested in phase I. The largest cohort tested included 296 patients with advanced solid tumours, including melanoma, NSCLC, renal cell carcinoma, prostate cancer, and colorectal cancer. This evidence concerns the gene PDCD1 and hereditary clear cell renal cell carcinoma.